This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 10.88% and 2.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Melinta Therapeutics, Inc. (MLNT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Oct 28, 2019
by Zacks Equity Research
Companies in the news are: AMZN, BOOM, RMD, MLNT
Implied Volatility Surging for Melinta Therapeutics (MLNT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Is a Beat in Store for Melinta (MLNT) This Earnings Season?
by Zacks Equity Research
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Melinta Therapeutics, Inc. (MLNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.
Melinta (MLNT) Announces Preliminary Product Sales for Q2
by Zacks Equity Research
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock
by Zacks Equity Research
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 52.38% and 97.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Melinta Therapeutics, Inc. (MLNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -32.69% and -0.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medicines Company to Sell Infectious Disease Unit to Melinta
by Zacks Equity Research
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Why Earnings Season Could Be Great for Cempra (MLNT)
by Zacks Equity Research
Cempra (MLNT) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.